The Motley Fool

Why I’d buy this top British FTSE 100 share for May and beyond

Image source: Getty Images.

The FTSE 100’s Smith & Nephew (LSE: SN) rose a little today on the release of what would normally be considered dire first-quarter trading figures. But these are not normal times.

The medical technology firm attracts me because it operates in a defensive industry with constant demand. At least under normal circumstances demand is steady. And we can see evidence of that in the company’s long record of gradually rising revenue, earnings operating cash flow, and shareholder dividends.

5G is here – and shares of this ‘sleeping giant’ could be a great way for you to potentially profit!

According to one leading industry firm, the 5G boom could create a global industry worth US$12.3 TRILLION out of thin air…

And if you click here we’ll show you something that could be key to unlocking 5G’s full potential...

Temporary collapse of demand

Smith & Nephew makes medical devices such as the replacement joints, fittings, nuts, bolts, rods, bits and pieces for skeletal joint and fracture repair. It also caters for advanced wound care and arthroscopic enabling technologies, among other things.  

However, normal medical operations around the world have been postponed to accommodate Covid-19 patients. Naturally, the share price plunged in the stock market crash. But it’s been coming back, and it looks like the move higher is continuing today.

Chief executive Roland Diggelmann said in today’s report, countries and healthcare systems around the world are facing “an unprecedented challenge.” And Smith & Nephew is suffering a “significant” hit to trade.  In the first quarter of the year to 28 March, revenue eased back just under 8% compared to last year’s figure.

However, in April, underlying revenue plunged around 47%, “reflecting suspension of elective procedures in most markets.” Yet it’s not all doom and gloom. The figure would have been worse but for improving trading in China.

Diggelmann described the recovery in China as “encouraging.” He reckons it marks the restart of elective surgeries in many other countries too, “especially within the US.” However, recovery in the company’s markets is likely to vary in pace and extent across geographies, he reckons.

Forecast to return to growth

Meanwhile, the company has been doing the usual things in the crisis. That includes reducing costs where it can and protecting its staff from the effects of the virus. Diggelmann assures us that the firm has the financial strength to withstand the uncertain period through the crisis. And the “robust” supply chain will combine with new ways of working to drive revenues as the company’s markets continue to recover.

There’s no forward-looking guidance on earnings for the time being from the directors. But the medium- and long-term outlooks are positive. My guess is that Smith & nephew will return to its gentle growth and expansion trajectory and the valuation will remain ‘reassuringly’ high.

I see this as a high-quality, enduring enterprise and would seek to take advantage of current weakness in the share price. I’d hold for the long term. My guess is that when looking back 10 years from today, I may be glad that I took the risk of picking up a few shares in Smith & Nephew during these troubled times.

“This Stock Could Be Like Buying Amazon in 1997”

I'm sure you'll agree that's quite the statement from Motley Fool Co-Founder Tom Gardner.

But since our US analyst team first recommended shares in this unique tech stock back in 2016, the value has soared.

What's more, we firmly believe there's still plenty of upside in its future. In fact, even throughout the current coronavirus crisis, its performance has been beating Wall St expectations.

And right now, we're giving you a chance to discover exactly what has got our analysts all fired up about this niche industry phenomenon, in our FREE special report, A Top US Share From The Motley Fool.

Click here to claim your copy now — and we’ll tell you the name of this Top US Share… free of charge!

Kevin Godbold has no position in any share mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

Our 6 'Best Buys Now' Shares

Renowned stock-picker Mark Rogers and his analyst team at The Motley Fool UK have named 6 shares that they believe UK investors should consider buying NOW.

So if you’re looking for more stock ideas to try and best position your portfolio today, then it might be a good day for you. Because we're offering a full 33% off your first year of membership to our flagship share-tipping service, backed by our 'no quibbles' 30-day subscription fee refund guarantee.

Simply click below to discover how you can take advantage of this.